

Factors associated with longitudinal plasma selenium decline in the elderly: The EVA study

Josiane Arnaud ^{1,2}, N.Tasmine Akbaraly ³, Isabelle Hininger ¹, Anne-Marie Roussel ¹,
Claudine Berr ³

Corresponding author: J Arnaud, DBI, CHU de Grenoble, BP 217, 38043 Grenoble cedex 9, France; tel: 33 4 76 76 54 84; fax: 33 4 76 76 58 21; e-mail: JArnaud@chu-grenoble.fr

1-NVMC (Nutrition, Vieillissement et Maladies Cardiovasculaires), Université Joseph Fourier, Domaine de La Merci, 38700 La Tronche, France.

2-DBI (Département de Biologie Intégrée), CHU de Grenoble, BP 217, 38043 Grenoble cedex 9, France.

3-INSERM E361, Montpellier, F-34000 France ; Université Montpellier1, Montpellier, F-34000 France.

Running title : Longitudinal Se decline in the elderly

Grants, sponsors and funding sources: The EVA (“Etude du Vieillissement Artériel”) study was carried out under an agreement between INSERM and the Merck, Sharp and Dohme-Chibret Laboratories (WestPoint, PA) and was supported by EISAI laboratory (France). N. Tasmine Akbaraly was supported by a grant from the French Alzheimer’s disease Association.

Key words: selenium decline, elderly, cardiovascular diseases, cardiovascular disease risk factors

Abstract:

Selenium status decreases in elderly populations. Cardiovascular diseases are the primary cause of death in French elderly and selenium may protect against cardiovascular diseases. The present work aims to evaluate the relationships between cardiovascular related risk factors and plasma selenium variability in an elderly population during a nine-year period. 751 subjects from the EVA ("Etude du Vieillissement Artériel") study, aged 59 to 71 at baseline were followed for 9 years. Clinical examinations and life style questionnaires were repeated every two years. Plasma selenium determinations were performed at baseline and at the end of the study. The association between the nine-year plasma selenium variability and studied risk factors at baseline or occurring during the follow-up was evaluated by using multivariate linear regression models. After controlling all potential associated factors, age of subjects ($p < 0.01$), obesity ($p = 0.02$) and occurrence of cardiovascular disease during follow-up ($p = 0.03$) increased the longitudinal decline in plasma selenium, whereas gender, education, smoking, alcohol intakes, dyslipidemia, diabetes, hypertension had no effect ($p > 0.05$). It may be postulated that obesity and occurrence of cardiovascular events are the main factors associated to plasma selenium fall during ageing. The respective roles played by nutritional and metabolism changes in the mechanism of these associations still need to be explored.

Introduction

Selenium is an essential trace element mainly involved in redox balance as part of glutathione peroxidases, thioredoxine reductase and selenoprotein P but also, more specifically, in cerebral function as part of selenoprotein P [1], thyroid function as part of iodine deiodinases, as well as in immune functions [2]. In the elderly, selenium status decreases slightly compared to younger adults as long as subjects are healthy but dramatically drops when subjects are institutionalised or ill [3, 4]. Recent epidemiological studies have suggested that an adequate selenium status in the elderly is associated with a lower mortality rate [5, 6] and a lower incidence of age related pathology [2, 6-10], possibly due to oxidative stress deleterious effect in ageing [11, 12]. Therefore, maintaining an adequate selenium status in the elderly may be of importance, particularly in Europe, where selenium intakes are low compared to recommended dietary daily intake, optimal glutathione peroxidase activity or immune functions [2, 3, 13, 14].

Cardiovascular diseases are the primary cause of death in France [15, 16] and low serum selenium concentrations have been reported to increase cardiovascular mortality and morbidity although the protective role of selenium against cardiovascular diseases remains debated [2]. Repeated measurements of plasma selenium concentration, a good biological indicator to evaluate selenium status [17], were performed on participants of the EVA study (“Etude du Vieillissement Artériel”); a nine-year longitudinal study whose aim was to examine determinants of cognitive and cardiovascular functions in a French elderly population [18].

In contrast to previous publications, the present work deals with the relationships between longitudinal plasma selenium variability during this study and main cardiovascular risk factors, cardiovascular disease occurrence or life style at baseline, as well as changes in health status or life style occurring during the nine-year follow-up.

Methods and Materials

Study population

From 1991 to 1993 (EVA0), 1389 volunteers (574 men and 815 women, mean age: 65; range: 59-71) residing in the town of Nantes (Western France) were recruited from electoral rolls, and to a lesser extent, via information campaigns. During the last follow-up of the EVA study (EVA6), between June 2000 and December 2001, blood sampling was obtained for 773 subjects. The present analysis is restricted to the 751 subjects (455 women and 296 men) who had a plasma selenium determination, both at baseline and at the end of the study, and focuses on the relationships between cardiovascular risk factors or cardiovascular disease occurrence and longitudinal plasma selenium variability. The study protocol was approved by the Ethical Committee of the University Center Hospital of Kremlin-Bicêtre (Paris). Signed informed consent was obtained from all participants at enrolment.

Questionnaire and medical examination

At baseline (EVA0) and at the end of the study (EVA6), a general questionnaire allowed us to obtain information on socio-demographic factors such as sex, age, educational achievement, marital status and tobacco and alcohol consumption habits. Alcohol consumption was

determined from the subject's estimated average amount of alcoholic beverages ingested weekly and expressed in g alcohol /day. In addition, height and weight were measured and body mass index (BMI) was calculated. Two independent measures of systolic and diastolic blood pressure were made with a digital electronic tensiometer after a 10-minute rest.

Biological variables

At baseline and at the end of the study blood samples were drawn between 8.30 am and 9.30 am after a 12-hour fast. Biological procedures for the determination of cholesterol and glucose levels have been described elsewhere [19]. Plasma selenium was determined by electrothermal atomic absorption spectrometry (Perkin Elmer 5100) according to a previously described method [20]. The spectrometer was fitted with a Zeeman background correction, a platform pyrolytical furnace and an electrodeless discharge lamp (EDL). Plasma was 5 fold diluted in a solution containing 0.2% Triton X100 and 0.1 mol nitric acid, and 15 µg platinum was used as a matrix modifier. Selenium concentration was obtained using standard addition calibration. Precision, expressed as within and between run coefficient of variations stood at 1.4 % and 1.8% respectively. Accuracy was checked by using Seronorm[®] trace element serum as an internal quality control (Sero[®], Billingstad, Norway) and the tolerance limits were ± 10 % of the batch target value in use. In addition, the laboratory took part in two external quality assessment schemes and its annual scores were **acceptable (values higher than 60%)**.

Statistical analysis

The characteristics of subjects at baseline were compared between two groups: those who had the two measurements of selenium at baseline and at the end of the study (complete

assessment, n=751) and those who did not (n=658). Results were expressed by percentage and means with their standard deviation (SD). To test differences between these two groups, Chi square test and Student's t-test were used. The characteristics at baseline and at the end of the follow-up of the 751 subjects who had the two plasma selenium measurements were also compared.

Plasma selenium concentrations at baseline and at the end of the study and corresponding plasma selenium differences were normally distributed and were analysed as continuous variables. Multivariate linear regression models were used to analyse factors associated to longitudinal plasma selenium variability. The first model studied the association between the studied factors at baseline and plasma selenium variability. In this model were included the following parameters: sex, age, education (no school or primary school *versus* high school or university) as a socio-economic level index [21], plasma selenium concentrations [22], marital status (single or not) as a loneliness index, tobacco status (current/ former/ non smokers), alcohol consumption (≥ 16 g *versus* <16 g per day [23]), obesity (BMI ≥ 30 kg/m² [24]), hypertension (systolic or diastolic blood pressure ≥ 140 or ≥ 90 mm Hg respectively, or use of hypertensive drugs or report of hypertension medical history), diabetes (plasma glucose level ≥ 7.80 mmol/l or use of anti-diabetic drugs or report of diabetes medical history), dyslipidemia (total cholesterol ≥ 6.2 mmol/l or use of lipid-lowering drugs or report of dyslipidemia medical history), and history of cardio-vascular diseases (myocardial infarction, angina pectoris, stroke or use of vascular drugs). In the second model, the association between changes in studied factors and plasma selenium variability was analyzed. The following variables were included in the model: smoking (non-smoker *versus* smoker or former smoker or stopped smoking during study), marital status (always *versus* never or becoming married during follow-up or becoming single), obesity (not obese *versus* obese or becoming obese or

becoming non-obese), diabetic (none *versus* previous history or onset), hypertensive (none *versus* previous history or onset), dyslipidemic (none *versus* previous history or onset), and cardiovascular diseases (none *versus* previous history or new occurrence). In addition, sex, age and education as main morbidity predictors and plasma selenium concentration at baseline [22] were included. All these potential explaining variables were included simultaneously. Statistical significance was defined by a p-value < 0.05. Statistical analyses were performed using SAS software version 9.1 (SAS Institute, Inc. Cary, North Carolina).

Results

At baseline 1389 subjects were included in the EVA study. Their main characteristics have been previously described as well as the influence of the studied factors on plasma selenium concentration at baseline [10, 18]. Among them, 54.1 % (n=751) completed the study. Drop out subjects lived alone less frequently (17.2% *versus* 24.2%, p=0.001), were more frequently men (44.8% *versus* 37,9%, p=0.009) and exhibited significantly more frequently hypertension (52.8% *versus* 46.5%, p=0.02), and obesity (12.3% *versus* 9.1%, p=0.05) than the subjects who completed the study, but they did not differ for baseline plasma selenium concentration (p=0.54), age (p=0.64), education (p=0.15), smoking (p=0.06), alcohol consumption (p=0.60), dyslipidemia (p=0.51), diabetes (p=0.36) and history of cardiovascular disease (p=0.08).

Reported characteristics of the population at the beginning and after nine years are shown in table 1. At baseline, mean plasma selenium concentration was equal to 1.10 $\mu\text{mol/l}$ and median was of 1.09 $\mu\text{mol/l}$. The maximum, 75th and 25th percentiles, and minimum plasma selenium values were 1.94, 1.23, 0.95 and 0.58 $\mu\text{mol/l}$ respectively. At the end of the follow-up, mean (minimum-maximum) plasma selenium concentrations decreased to 1.00 (0.48-

1.80) $\mu\text{mol/l}$, whereas median (25th – 75th percentiles) were of 0.99 (0.88-1.11) $\mu\text{mol/l}$.

During the follow-up, 4.9 % (n=24) of the subjects stopped smoking; 12.7% (n=95) became single whereas 1.7% (n=13) got married. Onset of diabetes, hypertension and dyslipemia and occurrence of cardio-vascular events were observed in 27 (3.7%), 248 (33.1%), 142 (19.3%) and 134 (17.8%) subjects respectively. In addition, 3.0% (n=17) of the participants became obese whereas BMI decreased to a value lower than 30 in 3.7% (n=21) of them. During the follow-up, a mean plasma selenium decline of $0.10 \pm 0.21 \mu\text{mol/l}$ was observed and the selenium decrease was estimated at $0.006 (\pm 0.002) \mu\text{mol/l}$ per year ($p < 0.0001$). The maximum decrease was of $0.97 \mu\text{mol/l}$. and the 75th percentile of the plasma selenium variation distribution was equal to $0.22 \mu\text{mol/l}$. A decrease in plasma selenium concentration was noted in 71.8% of subjects.

Results of multivariate linear regression models are presented in tables 2 and 3. Longitudinal plasma selenium decline was significantly associated with age ($p < 0.01$). Selenium fall was also significantly associated with plasma selenium level at baseline ($p < 0.0001$) due to the well-known regression to the mean phenomena's [22]. No significant association was observed between plasma selenium decline and other studied factors at baseline (table 2). Association between plasma selenium decline and studied factor modification during the study is indicated in table 3. The occurrence of cardiovascular events ($p = 0.03$) as well as lasting obesity ($p = 0.02$) significantly increased the fall in plasma selenium. No association was found between plasma selenium decrease and the other factors taken into account.

Discussion

Plasma selenium concentration largely depends on selenium intake and varies widely geographically [2, 9, 17]. Differences in plasma selenium concentrations between French regions have been reported in the SU.VI.M.AX study [25] and selenium status in the Nantes area is higher than in the East or the Center of France [25, 26]. The baseline plasma selenium concentrations observed in this study were similar to those reported in France in younger adults [26-28] and higher than plasma selenium concentrations reported in French institutionalized elderly populations [29, 30] in agreement with previous studies conducted in free-living elderly [3, 4]. It confirms that low plasma selenium concentrations in the elderly is especially found in those who are institutionalized [3, 4, 31], due to low intake [3, 29], reduced physical functioning [32] or severe pathologies [9] and can reflect undernutrition, lower bioavailability, increased requirements or metabolic changes. However, these values appear to be marginally lower than those necessary to achieve optimal activity of glutathione peroxidase, which occurs at plasma concentrations around 1.25 $\mu\text{mol/l}$ [2, 13, 17]. Sub-optimal selenium status may increase the susceptibility to various pathologies in elderly [2, 8-10, 13].

Numerous case-control or nested-control studies report plasma selenium concentrations in cardiovascular diseases [2, 33], and its main associated risk factors such as hypertension [34, 35], dyslipidemia [36-38], diabetes [39], smoking [40, 41], alcohol abuse [40, 41] and obesity [42] and the results are conflicting. To our knowledge this is the first report which focuses on longitudinal plasma selenium variability in a random free living elderly population. We observe a significant decline in plasma selenium concentrations in free-living subjects during the 9 year-follow-up. This decrease is more pronounced in older subjects in agreement with previous cross sectional studies conducted in Europe [43-46] but it contrasts with the third National Health and Nutrition Examination Survey results [47, 48] which show similar serum

selenium concentrations in adults and older people. These discrepancies may be related to difference in population characteristics. Among the studied risk factors, age, occurrence of cardiovascular diseases and obesity were pointed out as determinants of longitudinal plasma selenium decline. Smoking, alcohol consumption as well as previous history or onset of diabetes, dyslipidemia and hypertension had no significant effect on longitudinal plasma selenium decline in agreement with some previous case-control studies, which did not report any difference between cases and controls [34, 36-42, 49]. The positive relationship between age and longitudinal plasma selenium decrease observed in this study confirms the results of previous cross sectional European surveys [3, 4, 31, 43-46]. In addition, the cross sectional **relationship between** plasma **selenium** concentration **and** age in EVA was observed at the end (data not shown) of this study but not at baseline [18] confirming that the decline in plasma selenium with age may be delayed in free living elderly [43-45]. Cardiovascular disease occurrence during the follow-up significantly increased the longitudinal decline in plasma selenium. This observation, together with the lack of effect of previous history of cardiovascular events may contribute to the explanation of discrepancies reported in the literature [2, 33] concerning plasma selenium status and cardiovascular disease relationship and the effect of preventive selenium supplementation. Indeed, the longitudinal decline in plasma selenium concentration may be transient and linked to the significant decrease in plasma selenium reported during acute phase response [50], and therefore reflect more a consequence than a cause of the disease in people with plasma selenium concentration higher than the threshold value reported in different studies [2, 33]. Finally, our results show the adverse effect of obesity on longitudinal plasma selenium decline. Nevertheless, the association between longitudinal plasma selenium decrease and obesity became significant only in subjects with persistent obesity. This observation may contribute to explain discrepancies reported in the literature [25, 34, 37]. Obesity is associated with increased

oxidative stress due to insulin resistance, accumulation of intracellular triglycerides or increase in adipokine release [51, 52] and is a well known key factor for cardio-vascular diseases [53]. Taken together, our result suggests that obese elderly may need higher antioxidant, especially selenium, intake to counteract the higher oxidative stress, which leads to vascular oxidative dysfunction.

To the best of our knowledge, this epidemiological survey is the first which studies the association between cardiovascular risk factors or cardiovascular disease occurrence and selenium longitudinal variation in an elderly population. The results highlight the role of obesity and cardiovascular events in decreasing selenium status. Nonetheless, this preliminary data must be interpreted cautiously and needs to be confirmed on other elderly populations. Moreover, the respective importance of nutritional and metabolism changes in the mechanism of these associations still need to be explored.

References

1. Richardson DR. More roles for selenoprotein P: local selenium storage and recycling protein in the brain. *Biochem J* 2005;386:e5-7.
2. Thomson CD. Assessment of requirements for selenium and adequacy of selenium status: a review. *Eur J Clin Nutr* 2004;58:391-402.
3. Ducros V, Faure P, Ferry M, Couzy F, Biajoux I, Favier A. The sizes of the exchangeable pools of selenium in elderly women and their relation to institutionalization. *Br J Nutr* 1997;78:379-96.
4. Bates CJ, Thane CW, Prentice A, Delves HT. Selenium status and its correlates in a British national diet and nutrition survey: people aged 65 years and over. *J Trace Elem Med Biol* 2002;16:1-8.
5. Ray AL, Semba RD, Walston J, Ferrucci L, Cappola AR, Ricks MO, Xue QL, Fried LP. Low serum selenium and total carotenoids predict mortality among older women living in the community: the women's health and aging studies. *J Nutr* 2006;136:172-6.
6. Akbaraly NT, Arnaud J, Hininger-Favier I, Gourlet V, Roussel AM, Berr C. Selenium and mortality in the elderly: results from the EVA study. *Clin Chem* 2005;51:2117-23.
7. Rayman MP, Rayman MP. The argument for increasing selenium intake. *Proc Nutr Soc* 2002;61:203-15.
8. Patrick L. Selenium biochemistry and cancer: a review of the literature. *Altern Med Rev* 2004;9:239-58.
9. Combs GF. Selenium in global food systems. *Br J Nutr* 2001;85:517-47.
10. Berr C, Balansard B, Arnaud J, Roussel AM, Alperovitch A. Cognitive decline is associated with systemic oxidative stress: the EVA study. *Etude du Vieillissement Arteriel. J Am Geriatr Soc* 2000;48:1285-91.
11. Morley JE, Baumgartner RN. Cytokine-related aging process. *J Gerontol A Biol Sci Med Sci* 2004;59:M924-9.
12. Ferrucci L, Corsi A, Lauretani F, Bandinelli S, Bartali B, Taub DD, Guralnik JM, Longo DL. The origins of age-related proinflammatory state. *Blood* 2005;105:2294-9.

13. Rayman MP. Dietary selenium: time to act. *Br Med J* 1997;314:387-8.
14. Neve J. New approaches to assess selenium status and requirement. *Nutr Rev* 2000;58:363-9.
15. Jougl E, Salem G, Gancel S, Michel V. Atlas de la mortalité dans l'Union européenne. Luxembourg; 2002.
16. Haut Comité de la santé publique. La progression de la précarité en France et ses effets sur la santé. Rennes: ENSP; 1998.
17. Neve J. Methods in determination of selenium states. *J Trace Elem Electrolytes Health Dis* 1991;5:1-17.
18. Berr C, Coudray C, Bonithon-Kopp C, Roussel AM, Mainard F, Alperovitch A. Demographic and cardiovascular risk factors in relation to antioxidant status: the EVA Study. *Int J Vitam Nutr Res* 1998;68:26-35.
19. Bonithon-Kopp C, Touboul PJ, Berr C, Magne C, Ducimetiere P. Factors of carotid arterial enlargement in a population aged 59 to 71 years: the EVA study. *Stroke* 1996;27:654-60.
20. Arnaud J, Prual A, Preziosi P, Favier A, Hercberg S. Selenium determination in human milk in Niger: influence of maternal status. *J Trace Elem Electrolytes Health Dis* 1993;7:199-204.
21. Winkleby MA, Jatulis DE, Frank E, Fortmann SP. Socioeconomic status and health: how education, income, and occupation contribute to risk factors for cardiovascular disease. *Am J Public Health* 1992;82:816-20.
22. Macallan DC, Sedgwick P. Selenium supplementation and selenoenzyme activity. *Clin Sci (Lond)* 2000;99:579-81.
23. Hines LM, Rimm EB. Moderate alcohol consumption and coronary heart disease: a review. *Postgrad Med J* 2001;77:747-52.
24. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. *World Health Organ Tech Rep Ser* 2000;894:i-xii, 1-253.
25. Arnaud J, Bertrais S, Roussel AM, Arnault N, Ruffieux D, Favier A, Berthelin S, Estaquio C, Galan P, Czernichow S, Hercberg S. Serum selenium determinants in French adults: the SU.VI.M.AX study. *Br J Nutr* 2006;95:313-20.

26. Dubois F, Teby A, Belleville F, Nabet P, Paysant P. Valeurs usuelles du sélénium sérique dans une population de l'est de la France. *Ann Biol Clin (Paris)* 1990;48:28-32.
27. Simonoff M, Conri C, Fleury B, Berdeu B, Moretto P, Ducloux G, Llabador Y. Serum and erythrocyte selenium in normal and pathological states in France. *Trace Elem Med* 1988:64-9.
28. Arnaud J, Preziosi P. Réponse du zinc et du sélénium sériques au supplément vitaminique et minéral antioxydant chez des volontaires sains. *L'Eurobiologiste* 1994;28:161-5.
29. Schmuck A, Roussel AM, Arnaud J, Ducros V, Favier A, Franco A. Analyzed dietary intakes, plasma concentrations of zinc, copper, and selenium, and related antioxidant enzyme activities in hospitalized elderly women. *J Am Coll Nutr* 1996;15:462-8.
30. Monget AL, Galan P, Preziosi P, Keller H, Bourgeois C, Arnaud J, Favier A, Hercberg S. Micronutrient status in elderly people. *Geriatric/Min. Vit. Aux Network. Int J Vitam Nutr Res* 1996;66:71-6.
31. Gamez C, Ruiz-Lopez D, Artacho R, Navarro M, Puerta A, Lopez C. Serum selenium in institutionalized elderly subjects and relation to other nutritional markers. *Clin Chem* 1997;43:693-4.
32. de Jong N, Gibson RS, Thomson CD, Ferguson EL, McKensie JE, Green TJ, Horwath CC. Selenium and zinc status are suboptimal in a sample of older New Zealand women in a community-based study. *J Nutr* 2001;131:2677-84.
33. Alissa EM, Bahijri SM, Ferns GA. The controversy surrounding selenium and cardiovascular disease: a review of the evidence. *Med Sci Monit* 2003;9:RA9-18.
34. Telisman S, Jurasovic J, Pizent A, Cvitkovic P. Blood pressure in relation to biomarkers of lead, cadmium, copper, zinc, and selenium in men without occupational exposure to metals. *Environ Res* 2001;87:57-68.
35. Salonen JT, Alfthan G, Huttunen JK, Pikkarainen J, Puska P. Association between cardiovascular death and myocardial infarction and serum selenium in a matched-pair longitudinal study. *Lancet* 1982;2:175-9.
36. Lee O, Moon J, Chung Y. The relationship between serum selenium levels and lipid profiles in adult women. *J Nutr Sci Vitaminol (Tokyo)* 2003;49:397-404.

37. Koyama H, Watanabe C, Satoh H, Hosokai H, Tamura S. Consistent relationship between selenium and apolipoprotein A-II concentrations in the sera of fasting middle-aged male abstainers and regular consumers of alcohol. *Biol Trace Elem Res* 1995;50:33-42.
38. Delattre J, Lepage S, Jaudon MC, Bruckert E, Assogba U, Bonnefont-Rousselot D. Statut plasmatique en antioxydants et en oligoéléments de patients atteints d'hypercholestérolémie familiale traités par LDL-aphérèse. *Ann Pharm Fr* 1998;56:18-25.
39. Hadrzynski C. Diabetes and trace elements. *J Trace Elem Exp Med* 1999;12:367-74.
40. Robberecht H, Deelstra H. Factors influencing blood selenium concentration values: a literature review. *J Trace Elem Electrolytes Health Dis* 1994;8:129-43.
41. Alfthan G, Neve J. Reference values for serum selenium in various areas-evaluated according to the TRACY protocol. *J Trace Elem Med Biol* 1996;10:77-87.
42. Ringstad J, Jacobsen BK, Thomassen Y, Thelle DS. The Tromso Heart Study: serum selenium and risk of myocardial infarction a nested case-control study. *J Epidemiol Community Health* 1987;41:329-32.
43. Savarino L, Granchi D, Ciapetti G, Cenni E, Ravaglia G, Forti P, Maioli F, Mattioli R. Serum concentrations of zinc and selenium in elderly people: results in healthy nonagenarians/centenarians. *Exp Gerontol* 2001;36:327-39.
44. Ravaglia G, Forti P, Maioli F, Nesi B, Pratelli L, Savarino L, Cucinotta D, Cavalli G. Blood micronutrient and thyroid hormone concentrations in the oldest-old. *J Clin Endocrinol Metab* 2000;85:2260-5.
45. Olivieri O, Stanzial AM, Girelli D, Trevisan MT, Guarini P, Terzi M, Caffi S, Fontana F, Casaril M, Ferrari S, Corrocher R. Selenium status, fatty acids, vitamins A and E, and aging: the Nove Study. *Am J Clin Nutr* 1994;60:510-7.
46. Cals MJ, Bories PN, Blonde-Cynober F, Coudray-Lucas C, Desveaux N, Devanlay M, Duche JC, Luciani L, Meneguzzer E, Ponteziere C, Succari M, Tortrat D. Intervalles de référence et profil biologique d'une population de sujets âgés "en bonne santé" habitant la région parisienne. *Ann Biol Clin (Paris)* 1996;54:307-15.

47. Niskar AS, Paschal DC, Kieszak SM, Flegal KM, Bowman B, Gunter EW, Pirkle JL, Rubin C, Sampson EJ, McGeehin M. Serum selenium levels in the US population: Third National Health and Nutrition Examination Survey, 1988-1994. *Biol Trace Elem Res* 2003;91:1-10.
48. Kafai MR, Ganji V. Sex, age, geographical location, smoking, and alcohol consumption influence serum selenium concentrations in the USA: third National Health and Nutrition Examination Survey, 1988-1994. *J Trace Elem Med Biol* 2003;17:13-8.
49. Kardinaal AF, Kok FJ, Kohlmeier L, Martin-Moreno JM, Ringstad J, Gomez-Aracena J, Mazaev VP, Thamm M, Martin BC, Aro A, Kark JD, Delgado-Rodriguez M, Riemersma RA, van't Veer P, Huttunen JK. Association between toenail selenium and risk of acute myocardial infarction in European men. The EURAMIC Study. *European Antioxidant Myocardial Infarction and Breast Cancer. Am J Epidemiol* 1997;145:373-9.
50. Maehira F, Luyo GA, Miyagi I, Oshiro M, Yamane N, Kuba M, Nakazato Y. Alterations of serum selenium concentrations in the acute phase of pathological conditions. *Clin Chim Acta* 2002;316:137-46.
51. Keaney JF, Larson MG, Vasan RS, , Wilson PWF, Lipinska I, Corey D, Massaro JM, Sutherland P, Vita JA, Benjamin EJ. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. *Arterioscler Thromb Vasc Biol* 2003;23:434-9.
52. Fenster CP, Weinsier RL, Darley-USmar VM, Patel RP. Obesity, aerobic exercise, and vascular disease: the role of oxidant stress. *Obes Res* 2002;10:964-8.
53. Morrow JD. Is oxidant stress a connection between obesity and atherosclerosis? *Arterioscler Thromb Vasc Biol* 2003;23:368-70.

Table titles

Table 1: Characteristics of the 751 subjects at baseline and the end of the study

Table 2: Association between longitudinal plasma selenium decrease during the nine-year follow-up and risk factors measured at baseline. Results of linear regression models adjusted on all factors listed in the table

Table 3 : Association between longitudinal plasma selenium decrease and changes in risk factor during the nine-year follow-up. Results of linear regression models adjusted on all factors listed in the table